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Letters to the Editorperformed.4 Soppa and colleagues
might, therefore, achieve even better
surgical results using the sutureless
technique with significant improve-
ment in patient outcomes.5
We fully agree with Dr Soppa that
sutureless aortic valve replacement is
an ideal option for redo surgery,
such as was recently suggested by
our preliminary data in this patient
subset.6
We believe that sutureless aortic
valve prostheses have the potential to
shorten the surgical time, and future
research will determine whether this
advantage will also translate into
better outcomes in high-risk patients.
Sutureless aortic valve replacement
has been shown to be associated with
improved survival compared with
transcatheter aortic valve implanta-
tion, owing to the lower or no
rates of residual aortic regurgitation.
Only randomized prospective studies
comparing the 2 surgical techniques
will allow definite conclusions to be
drawn regarding this issue.
Giuseppe Santarpino, MD
Francesco Pollari, MD
Theodor Fischlein, MD
Department of Cardiac Surgery
Klinikum Nuremberg
Nuremberg, Germany
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With all due respect to the clinical
competence of Drs Delaere and Van
Raemdonck, we would like to address
their pointed critique as not only un-
substantiated but also demonstrably
false, which is both disturbing and
damaging to the field of tracheal
transplantation.1
The most disturbing comment is
‘‘more than half of the patients died
within a 3-month period.’’1 This is
incorrect. Of our first 9 clinical appli-
cations using a natural scaffold, only 1
died within the short-term period, and
the death was unrelated to the trans-
plantation. A report detailing these
cases is under review for publication.
We can firmly suggest tissue-
engineered tracheal replacement is
not ‘‘destined to fail’’ as evidenced
by survivors beyond 67 months.2
Second, the editorial states
‘‘Tracheal bioengineering was not
tested in animal models,’’ which is un-
true, based on our previous publica-
tions. In fact, in 1994, we described
the surgical technique for, and revas-
cularization of, tracheal allotransplan-
tations in pigs, published in this
Journal.3 To avoid immunosuppres-
sion, several large and small animal
models and in vitro airway transplan-
tation studies, not requiring immuno-
suppression were then completed and
published in peer-reviewed journals
(the number exceeded the reference
limit). All have supported the readi-
ness for ethical clinical application.
Additionally, advances in neoangio-
genesis, epithelial differentiation,
stem cell biology, and systemic and
in situ regenerative processes have
been reported.4,5 From this sound
preclinical evidence, human airwayof Thoracic and Cardiovascular Surgetransplantation has been approved by
national and local regulatory bodies
in 6 countries, including the US
Food and Drug Administration,
widely regarded as the world’s
toughest regulatory body.
Finally, Delaere and Van Raem-
donck suggested ‘‘dissemination of
misinformation’’ could be avoided
with ‘‘clear visualization of the tra-
chea.’’ Video endoscopy, high-
resolution computed tomography
scan images, and photomicrography
of the regenerated respiratory epithe-
lium, 5 years after transplantation
and without an airway stent in place
have, in fact, been published,2 and
whose evidence cannot be disputed.
We value the comments of Delaere
and Van Raemdonck and other leaders
in this field. We do not expect undis-
puted acceptance of our approach;
however, we would appreciate a
certain degree of collegiality and
respect for our unceasing efforts to
push for an innovative and scientifi-
cally sound solution for a vexing clin-
ical problem. The trachea is ‘‘one of
the most difficult organs in the human
body to replace.’’ Rebuilding an iden-
tical copy of the native airway might
not be possible; however, creating an
ideal, nonimmunogenic replacement
is. The best strategy for replacement
and regeneration has yet to be deter-
mined. Tissue-engineered tracheal
transplantation is still in its experi-
mental phase, far from routine clinical
application, and awaits the results of
an ongoing clinical trial (www.
clinicaltrials.gov). However, the as-
sertions that our preclinical and
translational advances in tracheal
transplantation are ‘‘misleading and
unrealistic’’ are overreaching, given
the extensive published data support-
ing the cells-to-bioartificial scaffold
interactions and documented long-
term survival of our own patient
series.
Finally, the editorial questions
whether the trachea is really the first
bioengineered organ. This claim has
never been made by us, but rather inry c Volume 148, Number 1 365
Letters to the Editora New York Times article describing
our work. Dr Anthony Atala has a
much better claim to this milestone
achievement.
Paolo Macchiarini, MD, PhD
Advanced Center for Translational
Regenerative Medicine
Division of Ear, Nose and Throat
Department for Clinical Science
Intervention and Technology
Karolinska Institutet
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We thank Dr Macchiarini for com-
menting on our editorial published in
the Journal, and we acknowledge his
team’s motivation and efforts to
advance tracheal replacement.
In his response to our editorial, Paolo
Macchiarini refers to several publica-
tions, thus undoubtedly convincing
many readers of his views. However,
in not one of these articles have morta-
lity rates been published. Furthermore,
we cannot follow his suggestion to rely
on an unpublished article to obtain this
information. Nor indeed can we refer
to its content, although we have been
in a position to read it. However, the un-
fortunate results after some of the treat-
ments with ‘‘bioengineered’’ tracheas366 The Journal of Thoracic and Chave reached investigative journalists
of Science1 and other media.2,3
More important, the purpose of our
editorial was to inform the scientific
community that regeneration of a
viable trachea resulting from applying
bone marrow cells to a decellularized
or a synthetic scaffold in the absence
of any blood supply is based on hope
and belief and not on scientific evi-
dence. None of the publications that
Macchiarini cites in his response pro-
vide scientific evidence for his claims.
We therefore strongly warn against
further unethical human experimenta-
tion. The ongoing clinical trials will
show whether or not this warning was
justified.
Pierre Delaere, MD, PhDa
Dirk Van Raemdonck, MD, PhDb
UZ Leuven
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FOR ACUTE KIDNEY INJURY
AFTER CORONARYARTERY
BYPASS GRAFTING
To the Editor:
We read with interest the recent
article by Ng and colleagues1 that
identified modifiable risk factors
for acute kidney injury (AKI) after
coronary artery bypass grafting
(CABG) in an Asian population.
They showed that preoperative anemia
and intraoperative lowest hematocrit
were potentially modifiable risk fac-
tors independently associated withardiovascular Surgery c July 2014postoperative AKI. In the design of
this study, however, some important
data regarding patient perioperative
management, such as intraoperative
hemodynamic changes, fluid volume,
and use of vasoactive medicines,
were evidently missing. It has been
shown that intraoperative systolic
blood pressure decrease relative to
baseline is independently associated
with postoperative AKI in patients un-
dergoing CABG.2 Furthermore, the
combination of intraoperative hemodi-
lution anemia and hypotension can
synergistically act to increase the risk
of AKI after cardiac surgery.3 Camp-
bell and associates4 have demonstrated
that fluid volume before cardiopulmo-
nary bypass can contribute signifi-
cantly to intraoperative hemodilution
anemia and that restricting fluid vol-
ume before cardiopulmonary bypass
can attenuate intraoperative hemodilu-
tion anemia and decrease the need for
transfusion in patients undergoing
CABG. In addition, perioperative ino-
tropes, vasopressors, antiarrhythmics,
and diureticsmay also influence devel-
opment of AKI after cardiac surgery.
We therefore argue that optimizing
perioperative management, such as in-
traoperative avoidance of excess fluid
volume, hypotension, and renal arte-
rial vasoconstrictive drugs, should be
importantly modifiable factors in
decreasing the occurrence of postoper-
ative AKI in patients undergoing
CABG. We believe that the results of
this studywould have beenmore infor-
mative had these factors been taken
into account.
Ng and colleagues1 did not mention
the specific timing of postoperative
creatinine measurements. It was also
unclear whether continuous creatinine
measurements were performed. It is
therefore difficult to determine
whether the cases of AKI reported in
this study were due to intraoperative
or postoperative factors. Although
serum creatinine lags behind acute
changes in renal function, AKI
(defined by serum creatinine >10
mmol/L greater than normal values)
